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Emerging evidence for the potential co-contributions of small vessel vasculopathy to dementia has resulted in a more
nuanced view of Alzheimer’s disease (AD) pathogenesis. Although cerebral small vessel disease, visualized on magnetic
resonance imaging as hyperintense signal abnormalities, independently predicts the incidence and clinical progression
of dementia, the relationships between AD pathology, white matter hyperintensity volume, genotype, and cognitive
decline in AD remain unclear. The study by Morgen and colleagues, recently published in Alzheimer’s Research &
Therapy, presents important new findings on the associations between apolipoprotien E ε4 genotype, white matter
hyperintensities, and cognition, independent of vascular risk, in a cohort of AD patients.Alzheimer’s disease (AD) is considered the most common
pathology contributing to dementia. Although genomic
analyses have identified the apolipoprotein E (apoE) ε4
allele as a major risk factor for late-onset AD, cerebral
small vessel disease (SVD) may also play a significant
role in decline to dementia. Despite increased efforts to
elucidate the complex relationships between AD, SVD,
and apoE genotype, the evidence remains equivocal, posing
a challenge for understanding the pathogenic mechanisms
underlying aging and dementia.
Prevailing models of AD pathogenesis suggest that
the aggregation of oligomeric amyloid-beta (Aβ) proteins
initiates a pathophysiological cascade hallmarked by extra-
cellular Aβ plaques in the interstitium and along cerebral
vessels, and intraneuronal neurofibrillary tangles of hyper-
phosphorylated tau. Neurodegenerative sequelae include
synaptic dysfunction, cortical atrophy, and progressive
cognitive decline. In vivo models of AD pathogenesis have
identified several potential mechanisms by which apoE ε4
may contribute to amyloidogenic processes (Fig. 1) [1].* Correspondence: jodi.edwards@sunnybrook.ca
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genesis has emerged, with evidence for the putative co-
contributions of vascular pathology. SVD is commonly
observed at autopsy in patients with AD and, although
neuropathological studies have consistently shown additive,
not interactive effects of vasculopathy [2], white matter
hyperintensities (WMHs) are more difficult to capture
at end-stage disease. Several neuroimaging-derived bio-
markers for SVD have been identified, including periven-
tricular and deep WMHs of presumed vascular origin,
lacunes, and enlarged perivascular Virchow-Robin spaces,
which may be visualized earlier in disease progression [3].
Recent studies using amyloid positron emission tomog-
raphy (PET) support a relationship between SVD and
amyloid pathology [4], but also confirm that significant
subcortical ischemic vasculopathy alone may be sufficient
to cause dementia [5]. Combined with early clinical evi-
dence for the role of apoE ε4 in the development of
cerebral amyloid angiopathy independent of AD [6],
and observational associations between dementia and
vascular risk factors, these advances have initiated new
lines of investigation into whether white matter vasculopa-
thy represents a synergistic or independent mechanism of
AD pathogenesis.
In a recent article in Alzheimer’s Research & Therapy,
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Fig. 1 Effects of apolipoprotein E (apoE) ε4 on amyloid-beta (Aβ) metabolism and deposition. apoE may facilitate cellular uptake of Aβ by the
endocytosis of apoE-containing lipoprotein particles bound to soluble Aβ (yellow circles), or via binding of this apoE-Aβ complex (mauve-blue circles) to
extracellular heparin sulfate proteoglycans (HSPG). Alternatively, apoE may impair Aβ clearance by slowing the transport of Aβ across the blood–brain
barrier [1]. LDLR, low-density lipoprotein receptor; LRP, lipoprotein receptor-related protein; PgP, permeability-glycoprotein. Reproduced with
permission from Elsevier [1]
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tive performance in a cohort of patients with mild to mod-
erate AD (N = 183). They compared apoE ε4 carriers to
non-carriers with respect to global and regional WMH
volume and performance on standardized neuropsycho-
logical tests. Results indicated that apoE ε4 carriers
showed reduced WMH volumes compared with non-
carriers and, among non-carriers, global WMH volume
was correlated with performance on the Trail Making
Test-A of executive function. The authors interpreted
these findings as evidence that WMHs had a functional
impact on cognition and that SVD represents an inde-
pendent mechanism of AD pathogenesis.
The Morgen et al. study is consistent with prior work
demonstrating that WMHs primarily impact the domain
of executive function [8] and are associated with amyloid
plaques on Pittsburg compound B retention PET in apoE
ε4 non-carriers with subcortical vascular cognitive impair-
ment [9]. In a recent meta-analysis of 42 studies, however,
an association between apoE ε4 and magnetic resonance
imaging markers of cerebrovascular disease was reported
[10], suggesting that vascular mechanisms may differentially
co-contribute to multiple pathophysiological cascades with
distinct clinical sequelae.
A strength of the Morgen et al. study [7] is in the spe-
cificity of case selection. To minimize the potential for
misclassification, the authors excluded those with ‘severe’
WMH burden suggestive of vascular dementia accordingto new AD diagnostic guidelines [11]. They then adjusted
all multivariate models for multiple vascular risk factors,
to increase the likelihood of observing apoE-dependent
effects. In restricting their cohort to patients without a
presumed vascular etiology, Morgen et al. provide novel
evidence for an association between WMH and apoE
genotype that modified executive function independent of
vascular risk.
A major source of bias in clinical imaging studies is
that template-matching approaches, such as statistical
parametric mapping, do not include a head size correc-
tion or account for cortical atrophy. In many clinical
populations, particularly AD, the degree of atrophy is
high, impacting ventricle size and total intracranial vol-
ume and resulting in the potential misattribution of
WMH to the grey matter tissue compartment [12]. To
partially address this limitation, Morgen et al. corrected
for total intracranial volume and still showed greater
WMH burden in apoE ε4 non-carriers, strengthening
their argument that this association reflects pathogenic
mechanisms of AD independent of apoE ε4-mediated
neurodegeneration.
As arterial hypertension correlated with WMHs in
their cohort, Morgen et al. suggest blood pressure may have
synergistic effects on amyloid-mediated endothelial dam-
age. Recent animal studies have described a 'G-lymphatic'
system that removes amyloid in the perivascular spaces
toward the deep periventricular veins [13] and confirmed
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collagenosis in spontaneously hypertensive rats [14].
Neuropathological analyses also suggest that periventricular
WMHs may represent perivenular vasogenic edema correl-
ating with collagenosis of the deep medullary venules [15].
Venous insufficiency thus represents a potential mechan-
ism of impaired Aβ clearance that may exacerbate amyloid
accumulation and increase clinical decline into dementia.
Increasing evidence for the role of small vessel vascu-
lopathy in dementia highlights the importance of multi-
factorial mechanisms in AD pathogenesis. The findings
of Morgen and colleagues are timely and offer support
for the co-contributions of WMHs to cognitive impairment
in AD, not mediated by apoE ε4 genotype. A greater
understanding of amyloid clearance will be required for
the development of targeted therapies to mitigate the risk
and clinical progression of AD. Amyloid PET imaging
offers new opportunities to elucidate additive/interactive
effects of WMHs in AD and unravel the pathogenic mech-
anisms of this complex phenotype.
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